Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Craig ERICKSON |
Documents disponibles écrits par cet auteur (22)
Faire une suggestion Affiner la recherche
Psychopharmacological Treatment of Autism / Kelly BLANKENSHIP
Titre : Psychopharmacological Treatment of Autism Type de document : Texte imprimé et/ou numérique Auteurs : Kelly BLANKENSHIP, Auteur ; Craig ERICKSON, Auteur ; Kimberly A. STIGLER, Auteur ; David J. POSEY, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2011 Importance : p.1196-1214 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=140 Psychopharmacological Treatment of Autism [Texte imprimé et/ou numérique] / Kelly BLANKENSHIP, Auteur ; Craig ERICKSON, Auteur ; Kimberly A. STIGLER, Auteur ; David J. POSEY, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2011 . - p.1196-1214.
Langues : Anglais (eng)
Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=140 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire Psychopharmacology / Craig ERICKSON
Titre : Psychopharmacology Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Kimberly A. STIGLER, Auteur ; David J. POSEY, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2007 Importance : p.221-253 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=796 Psychopharmacology [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Kimberly A. STIGLER, Auteur ; David J. POSEY, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2007 . - p.221-253.
Langues : Anglais (eng)
Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=796 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire Psychopharmacology of Autism Spectrum Disorders / Lindsey MOONEY
Titre : Psychopharmacology of Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Lindsey MOONEY, Auteur ; Cara FOSDICK, Auteur ; Craig ERICKSON, Auteur Année de publication : 2019 Importance : p.158-175 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 Psychopharmacology of Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Lindsey MOONEY, Auteur ; Cara FOSDICK, Auteur ; Craig ERICKSON, Auteur . - 2019 . - p.158-175.
Langues : Anglais (eng)
Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers / Rebecca C. SHAFFER in Journal of Autism and Developmental Disorders, 53-5 (May 2023)
[article]
Titre : Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers Type de document : Texte imprimé et/ou numérique Auteurs : Rebecca C. SHAFFER, Auteur ; Lauren M. SCHMITT, Auteur ; Debra L. REISINGER, Auteur ; Marika COFFMAN, Auteur ; Paul HORN, Auteur ; Matthew S. GOODWIN, Auteur ; Carla MAZEFSKY, Auteur ; Shelley RANDALL, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.1942-1962 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Individuals with autism spectrum disorder (ASD) experience behavioral and emotional symptoms hypothesized to arise from emotion dysregulation (ED), difficulty modulating emotional experience, expression, and intensity in an acceptable and contextually appropriate manner. We developed Regulating Together (RT)-an intensive-outpatient, caregiver-assisted group program to meet the ASD?+?ED intervention critical need. A within-subjects trial was conducted (5-week-control lead-in period, 5-week-treatment, and 5-and 10-weeks-post-treatment follow-ups). Forty-four youth with ASD?+?ED (25 8-12, 19 13-18 yr-olds, 88% male, mean FSIQ of 96) participated. Improvements were found in reactivity, emotion regulation knowledge, and flexibility post-treatment and 10-weeks post-treatment. A reduction in inpatient hospitalization rates by 16% from the 12 months pre-RT to 12 months post-RT was observed. RT shows promise to reduce ED in ASD. En ligne : https://doi.org/10.1007/s10803-022-05461-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=501
in Journal of Autism and Developmental Disorders > 53-5 (May 2023) . - p.1942-1962[article] Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers [Texte imprimé et/ou numérique] / Rebecca C. SHAFFER, Auteur ; Lauren M. SCHMITT, Auteur ; Debra L. REISINGER, Auteur ; Marika COFFMAN, Auteur ; Paul HORN, Auteur ; Matthew S. GOODWIN, Auteur ; Carla MAZEFSKY, Auteur ; Shelley RANDALL, Auteur ; Craig ERICKSON, Auteur . - p.1942-1962.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 53-5 (May 2023) . - p.1942-1962
Index. décimale : PER Périodiques Résumé : Individuals with autism spectrum disorder (ASD) experience behavioral and emotional symptoms hypothesized to arise from emotion dysregulation (ED), difficulty modulating emotional experience, expression, and intensity in an acceptable and contextually appropriate manner. We developed Regulating Together (RT)-an intensive-outpatient, caregiver-assisted group program to meet the ASD?+?ED intervention critical need. A within-subjects trial was conducted (5-week-control lead-in period, 5-week-treatment, and 5-and 10-weeks-post-treatment follow-ups). Forty-four youth with ASD?+?ED (25 8-12, 19 13-18 yr-olds, 88% male, mean FSIQ of 96) participated. Improvements were found in reactivity, emotion regulation knowledge, and flexibility post-treatment and 10-weeks post-treatment. A reduction in inpatient hospitalization rates by 16% from the 12 months pre-RT to 12 months post-RT was observed. RT shows promise to reduce ED in ASD. En ligne : https://doi.org/10.1007/s10803-022-05461-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=501 STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)
[article]
Titre : STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Jeremy M. VEENSTRA-VANDERWEELE, Auteur ; Raun D. MELMED, Auteur ; James T. MCCRACKEN, Auteur ; Lawrence D. GINSBERG, Auteur ; Linmarie SIKICH, Auteur ; Lawrence SCAHILL, Auteur ; Maryann CHERUBINI, Auteur ; Peter ZAREVICS, Auteur ; Karen WALTON-BOWEN, Auteur ; Randall L. CARPENTER, Auteur ; Mark F. BEAR, Auteur ; Paul P. WANG, Auteur ; Bryan H. KING, Auteur Année de publication : 2014 Article en page(s) : p.958-964 Langues : Anglais (eng) Mots-clés : STX209 Arbaclofen Gamma-aminobutyric acid (GABA) Autism spectrum disorder Clinical trial Index. décimale : PER Périodiques Résumé : STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ?17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted. En ligne : http://dx.doi.org/10.1007/s10803-013-1963-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228
in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.958-964[article] STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Jeremy M. VEENSTRA-VANDERWEELE, Auteur ; Raun D. MELMED, Auteur ; James T. MCCRACKEN, Auteur ; Lawrence D. GINSBERG, Auteur ; Linmarie SIKICH, Auteur ; Lawrence SCAHILL, Auteur ; Maryann CHERUBINI, Auteur ; Peter ZAREVICS, Auteur ; Karen WALTON-BOWEN, Auteur ; Randall L. CARPENTER, Auteur ; Mark F. BEAR, Auteur ; Paul P. WANG, Auteur ; Bryan H. KING, Auteur . - 2014 . - p.958-964.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.958-964
Mots-clés : STX209 Arbaclofen Gamma-aminobutyric acid (GABA) Autism spectrum disorder Clinical trial Index. décimale : PER Périodiques Résumé : STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ?17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted. En ligne : http://dx.doi.org/10.1007/s10803-013-1963-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 The autism inpatient collection: methods and preliminary sample description / Matthew SIEGEL in Molecular Autism, (November 2015)
PermalinkThe Neurochemistry of ASD / David J. POSEY
Permalink